ANAVEX LIFE SCIENCES CORP.

Anavex Life Sciences is a biopharmaceutical company developing treatments for central nervous system disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and various cancers. The company's approach focuses on restoring cellular homeostasis through sigma-1 receptor and muscarinic receptor targeting. Its lead candidate, ANAVEX 2-73 (blarcamesine), is an orally administered drug that has progressed through multiple clinical trials across several indications. The compound has completed Phase 2b/3 testing in Alzheimer's disease, Phase 2 proof-of-concept studies in Parkinson's disease dementia, and Phase 2/3 trials in both adult and pediatric Rett syndrome patients. In preclinical studies, ANAVEX 2-73 demonstrated anticonvulsant, neuroprotective, and anti-amnesic properties.

The company also maintains a secondary pipeline asset, ANAVEX 3-71, a clinical-stage candidate targeting sigma-1 and M1 muscarinic receptors. This compound has shown disease-modifying activity against cognitive deficits, amyloid pathology, and tau pathology in animal models of Alzheimer's disease.

Anavex operates with a staff of 34 full-time employees and maintains headquarters in New York. The company is incorporated in the United States and listed on Nasdaq. As a clinical-stage biopharmaceutical firm, the company's revenue streams are limited to research funding and potential milestone-based partnerships, with primary focus directed toward advancing its pipeline candidates through clinical development.